bromperidol: bromine-substituted for chlorine in haloperidol; RN given refers to unlabeled parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 2448 |
| CHEMBL ID | 28218 |
| CHEBI ID | 31305 |
| SCHEMBL ID | 43755 |
| MeSH ID | M0049599 |
| Synonym |
|---|
| MLS002153852 |
| smr001233211 |
| BRD-K78643075-001-03-3 |
| 4-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one |
| butyrophenone, 4-(4-(p-bromophenyl)-4-hydroxypiperidino)-4'-fluoro- |
| 1-butanone, 4-(4-(4-bromophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)- |
| brn 1552256 |
| 4-(4-(p-bromophenyl)-4-hydroxypiperidinol)-4'-fluorobutyrophenone |
| bromperidolum [inn-latin] |
| 4-(4-(p-bromophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone |
| cc 2489 |
| impromen |
| c21h23brfno2 |
| einecs 233-943-3 |
| 4-(4-(4-bromophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone |
| 4-(4-(4-bromophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone |
| r 11333 |
| PDSP1_001125 |
| bromperidol |
| PRESTWICK_781 |
| 10457-90-6 |
| cas-10457-90-6 |
| NCGC00016692-01 |
| BPBIO1_000481 |
| BSPBIO_000437 |
| PDSP2_001109 |
| NCGC00179558-01 |
| PRESTWICK3_000509 |
| D01101 |
| impromen (tn) |
| bromperidol (jan/usan/inn) |
| PRESTWICK0_000509 |
| SPBIO_002358 |
| PRESTWICK1_000509 |
| PRESTWICK2_000509 |
| HMS2093J06 |
| nsc-759275 |
| r-11333 |
| r 11,333 |
| CHEMBL28218 |
| L000662 |
| HMS1569F19 |
| bromoperidol |
| cas_2448 |
| nsc_2448 |
| bdbm81484 |
| HMS2096F19 |
| tesoprel |
| bromperidolum |
| nsc 759275 |
| lyh6f7i22e , |
| bromperidol [usan:inn:ban:jan] |
| unii-lyh6f7i22e |
| 5-21-02-00382 (beilstein handbook reference) |
| pharmakon1600-01505972 |
| nsc759275 |
| dtxcid102690 |
| tox21_110565 |
| dtxsid0022690 , |
| HMS2230O05 |
| NCGC00016692-02 |
| 4-[4-(4-bromo-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one |
| FT-0630383 |
| 4-[4-(4-bromophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)butan-1-one |
| AKOS015914052 |
| 4-[4-(4-bromophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone |
| azurene |
| HMS3370C12 |
| bromperidol [who-dd] |
| bromperidol [ep monograph] |
| bromperidol [usan] |
| bromperidol [mi] |
| bromperidol [mart.] |
| bromperidol [jan] |
| bromperidol [inn] |
| bromperidol decanoate impurity g [ep impurity] |
| CCG-213579 |
| SCHEMBL43755 |
| tox21_110565_1 |
| NCGC00016692-05 |
| 4-[4-(4-bromophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one |
| 1-butanone, 4-[4-(4-bromophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)- |
| 1-butanone, 4-[4-(4-bromophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)- |
| 4-(4-(4-bromophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one , |
| HY-B0901 |
| J-001195 |
| bromperidol, european pharmacopoeia (ep) reference standard |
| SR-05000001811-3 |
| sr-05000001811 |
| SR-05000001811-1 |
| CHEBI:31305 |
| SBI-0206864.P001 |
| HMS3713F19 |
| 4-[4-(p-bromophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone;4-[4-(p-bromophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone |
| DB12401 |
| Q4973749 |
| BRD-K78643075-001-06-6 |
| bromperidol; 4-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one |
| A896205 |
| F85189 |
| MS-27369 |
| r-11333r-11333 |
| EN300-19767176 |
Bromperidol (BRP) is an analog of haloperidol, a potent butyrophenone neuroleptic. Its metabolic pathways are similar to those of halopersidol.
Bromperidol has a potent antipsychotic action and some stimulating properties on activity. It is useful when increasing patients' motivation, and resocialization is at stake.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Bromperidol has a potent antipsychotic action and some stimulating properties on activity which make it very useful when increasing patients' motivation, and resocialization is at stake." | ( [Treatment with bromperidol in schizophrenic patients]. Ellerman, LA, ) | 1.2 |
| "Bromperidol has a potent antipsychotic action, and some stimulating properties on activity which make it very useful when increasing patients' motivation, and resocialization is at stake." | ( [Treatment with bromperidol in schizophrenic patients]. Ellerman, LA, 1988) | 1.34 |
| "Bromperidol has a potent antipsychotic action and some stimulating properties on activity which make it very useful when increasing patients' motivation, and resocialization is at stake." | ( [Treatment with bromperidol in schizophrenic patients]. Ellerman, LA, ) | 1.2 |
| "Bromperidol has a potent antipsychotic action, and some stimulating properties on activity which make it very useful when increasing patients' motivation, and resocialization is at stake." | ( [Treatment with bromperidol in schizophrenic patients]. Ellerman, LA, 1988) | 1.34 |
Bromperidol treatment significantly (P < 0.01) increased plasma concentration of prolactin each week. Treatment of bromperodol caused sedation of pregnant females in 1.5 and 10.0 mg/kg groups.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Bromperidol treatment significantly (P < 0.01) increased plasma concentration of prolactin each week." | ( Prolactin response to bromperidol treatment in schizophrenic patients. Inoue, Y; Ishida, M; Kaneko, S; Kondo, T; Mihara, K; Otani, K; Suzuki, A; Yasui, N, 1998) | 1.34 |
| "Treatment of bromperidol caused sedation of pregnant females in 1.5 and 10.0 mg/kg groups with concomitant decrease in body weight and in food and water intake in dose-dependent manner." | ( [Teratogenicity study on bromperidol in rats]. Huang, KJ; Imai, S; Sudo, T; Takeshima, T; Tauchi, K, 1984) | 0.92 |
The relationship between Taq1 A polymorphism of dopamine D(2) receptor (DRD(2)) gene and extrapyramidal adverse effects of bromperidol and nemonapride was investigated in Japanese schizophrenic inpatients.
| Excerpt | Reference | Relevance |
|---|---|---|
| "The relationship between Taq1 A polymorphism of dopamine D(2) receptor (DRD(2)) gene and extrapyramidal adverse effects of bromperidol and nemonapride, which are both antipsychotic drugs with selective and potent DRD(2) antagonistic property, was investigated in Japanese schizophrenic inpatients." | ( No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study. Kaneko, S; Kondo, T; Mihara, K; Nagashima, U; Ono, S; Otani, K; Suzuki, A, 2000) | 0.71 |
| " The present study aims to investigate the relationship between the -141C Ins/Del polymorphism and extrapyramidal adverse effects of bromperidol and nemonapride, antipsychotic drugs with a selective and potent DRD2 antagonistic property, in schizophrenic inpatients." | ( No relationship between--141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study. Kaneko, S; Kondo, T; Mihara, K; Ono, S; Otani, K; Suzuki, A; Yasui, N, 2001) | 0.51 |
Pharmacokinetic and pharmacodynamic interactions between the gastrokinetic drug cisapride and the antipsychotic drugs bromperidol and haloperidol were studied in 29 schizophrenic inpatients.
| Excerpt | Reference | Relevance |
|---|---|---|
| " Both agents possess similar pharmacodynamic properties which are consistent with central antidopaminergic activity." | ( Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses. Benfield, P; Clark, BG; Jue, SG; Ward, A, 1988) | 1.72 |
| "Pharmacokinetic and pharmacodynamic interactions between the gastrokinetic drug cisapride and the antipsychotic drugs bromperidol and haloperidol were studied in 29 schizophrenic inpatients." | ( No pharmacokinetic but pharmacodynamic interactions between cisapride and bromperidol or haloperidol. Furukori, H; Inoue, Y; Ishida, M; Kaneko, S; Kondo, T; Mihara, K; Nagashima, U; Otani, K; Suzuki, A; Yasui, N, 1999) | 0.74 |
| "We have presented pharmacokinetic parameters of bromperidol (BP) in 14 healthy Korean subjects." | ( Pharmacokinetic parameters of bromperidol in Korean subjects. Kim, HG; Kim, JW; Kim, YG; Lee, SY, 2006) | 0.88 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The employed dosage caused no strong sedation." | ( Double-blind comparison of bromperidol and perphenazine. Angst, J; Woggon, B, 1978) | 0.56 |
| " The dosage calculation was made from the haloperidol doses previously received by the patients, adjusted in each particular case, with a mean of 73 mg per application (range, 50 to 200 mg)." | ( [Chronic treatment of schizophrenia with injectable bromperidol decanoate]. Suárez Richards, M, 1985) | 0.52 |
| " The same was true for haloperidol plasma levels after chronic dosing in man." | ( Radioimmunoassay of bromperidol and haloperidol in human and canine plasma. Belpaire, FM; Bogaert, MG; De Moerloose, P; Van Den Eeckhout, E, 1980) | 0.58 |
| " These findings suggest that acute dystonia is affected by age factor, and that daily dosage or monitoring of drug concentration is unlikely to be a useful marker for the prediction of side-effects during bromperidol treatment." | ( The characteristics of side-effects of bromperidol in schizophrenic patients. Ishida, M; Kaneko, S; Kondo, T; Mihara, K; Otani, K; Tanaka, O; Yasui-Furukori, N, 2002) | 0.77 |
| Class | Description |
|---|---|
| aromatic ketone | A ketone in which the carbonyl group is attached to an aromatic ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 7.9433 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 20.4947 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 25.1189 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
| TDP1 protein | Homo sapiens (human) | Potency | 18.2622 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 10.9408 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 28.7466 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 33.4915 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 32.5548 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 12.5115 | 0.0123 | 7.9835 | 43.2770 | AID1346984; AID1645841 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 29.8493 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 18.9959 | 0.0008 | 17.5051 | 59.3239 | AID1159527 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 26.2693 | 0.0015 | 30.6073 | 15,848.9004 | AID1224848; AID1224849; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 10.9056 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID1346985 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 2.7540 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| polyprotein | Zika virus | Potency | 25.1189 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
| caspase-3 | Homo sapiens (human) | Potency | 33.4915 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| IDH1 | Homo sapiens (human) | Potency | 2.5929 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 26.6032 | 0.0016 | 28.0151 | 77.1139 | AID1259385 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 3.9811 | 0.0020 | 7.5337 | 39.8107 | AID891 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 14.5810 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 0.1259 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 10.1235 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 23.7083 | 0.0006 | 27.2152 | 1,122.0200 | AID743202 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 10.0000 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 12.5893 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 12.5893 | 0.0063 | 8.2350 | 39.8107 | AID881 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 39.8107 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| N-acetyltransferase Eis | Mycobacterium tuberculosis H37Rv | IC50 (µMol) | 0.5200 | 0.3900 | 1.6425 | 5.1000 | AID1853637 |
| N-acetyltransferase Eis | Mycobacterium tuberculosis H37Rv | Ki | 0.2400 | 0.2400 | 0.3150 | 0.3900 | AID1853645 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| iron ion binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| calcium ion binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| protein binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| lipid binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| linoleate 13S-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| arachidonate 8(S)-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| arachidonate 15-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| linoleate 9S-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| N-acetyltransferase activity | N-acetyltransferase Eis | Mycobacterium tuberculosis H37Rv |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID18348 | Tested for the tissue distribution of Br activity at 60 min in blood following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14297 | Distribution in rat heart 8 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18337 | Tested for the tissue distribution of Br activity at 15 min in lungs following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14126 | Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1853653 | Antibacterial activity against Mycobacterium bovis BCG ATCC 35734 assessed as inhibition of bacterial growth incubated upto 3 weeks hrs by resazurin dye based double-dilution method | 2021 | RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11 | Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from |
| AID14299 | Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14139 | Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14496 | Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18351 | Tested for the tissue distribution of Br activity at 60 min in liver following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14314 | Distribution in rat liver 15 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14148 | Distribution in rat fat 8 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14135 | Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14340 | Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14510 | Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID14130 | Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID18331 | Tested for the tissue distribution of Br activity at 120 min in liver following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14335 | Distribution in rat muscle 5 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14324 | Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14150 | Distribution in rat heart 1 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14144 | Distribution in rat fat 30 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14343 | Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14502 | Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18341 | Tested for the tissue distribution of Br activity at 30 min in liver following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID18350 | Tested for the tissue distribution of Br activity at 60 min in kidney following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID1853638 | Potentiation of kanamycin-induced antibacterial activity against Mycobacterium tuberculosis H37Rv assessed as kanamycin MIC incubated for 1 day followed by kanamycin addition for 6 days and by Alamar blue assay | 2021 | RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11 | Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from |
| AID14498 | Distribution in rat spleen 30 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14495 | Distribution in rat spleen 15 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18340 | Tested for the tissue distribution of Br activity at 30 min in kidney following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID14301 | Distribution in rat intestine 30 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID14311 | Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18346 | Tested for the tissue distribution of Br activity at 45 min in liver following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14323 | Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14316 | Distribution in rat liver 2 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18334 | Tested for the tissue distribution of Br activity at 15 min in brain following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14500 | Distribution in rat spleen 5 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14318 | Distribution in rat liver 4 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18330 | Tested for the tissue distribution of Br activity at 120 min in kidney following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| AID14503 | Distribution in rat uterus 15 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14136 | Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1853639 | Potentiation of kanamycin-induced antibacterial activity against Mycobacterium tuberculosis K204 assessed as kanamycin MIC incubated for 1 day followed by kanamycin addition for 6 days and by Alamar blue assay | 2021 | RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11 | Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from |
| AID14333 | Distribution in rat muscle 30 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14320 | Distribution in rat liver 6 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14298 | Distribution in rat intestine 15 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14305 | Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14493 | Distribution in rat skin 6 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14494 | Distribution in rat skin 8 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID14508 | Distribution in rat uterus 5 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14142 | Distribution in rat fat 1 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14312 | Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14300 | Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1853650 | Antibacterial activity against Mycobacterium abscessus ATCC 19977 assessed as inhibition of bacterial growth incubated upto 3 weeks hrs by resazurin dye based double-dilution method | 2021 | RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11 | Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from |
| AID14327 | Distribution in rat lungs 5 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14334 | Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14147 | Distribution in rat fat 6 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18333 | Tested for the tissue distribution of Br activity at 15 min in blood following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14137 | Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14505 | Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14488 | Distribution in rat skin 1 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14321 | Distribution in rat liver 8 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14132 | Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID14337 | Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18343 | Tested for the tissue distribution of Br activity at 45 min in blood following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14295 | Distribution in rat heart 5 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1853655 | Antibacterial activity against Mycobacterium tuberculosis mc2 6230 with Eis C-14T mutation assessed as inhibition of bacterial growth incubated upto 3 weeks hrs by resazurin dye based double-dilution method | 2021 | RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11 | Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from |
| AID14499 | Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14489 | Distribution in rat skin 2 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14330 | Distribution in rat muscle 15 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18143 | Tested for the tissue distribution of Br activity at 120 min in brain following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14501 | Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18338 | Tested for the tissue distribution of Br activity at 30 min in blood following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID18345 | Tested for the tissue distribution of Br activity at 45 min in kidney following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID1853651 | Antibacterial activity against Mycobacterium intracellulare ATCC 13950 assessed as inhibition of bacterial growth incubated upto 3 weeks hrs by resazurin dye based double-dilution method | 2021 | RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11 | Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from |
| AID1853654 | Antibacterial activity against Mycobacterium tuberculosis H37Ra ATCC NRS22 assessed as inhibition of bacterial growth incubated upto 3 weeks hrs by resazurin dye based double-dilution method | 2021 | RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11 | Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from |
| AID1853637 | Inhibition of Mycobacterium tuberculosis Eis assessed as Eis-mediated kanamycin acetylation preincubated for 10 mins followed by substrate addition and measured for 2 to 5 mins using acetyl-CoA as substrate in presence of kanamycin by UV-Vis spectroscopy | 2021 | RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11 | Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from |
| AID1853667 | Synergistic antibacterial activity against Mycobacterium smegmatis mc2 155 assessed as fold reduction in MIC value at 8 ug/ml in presence of spectinomycin by checkerboard assay | 2021 | RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11 | Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from |
| AID14507 | Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14304 | Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14151 | Distribution in rat heart 2 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14294 | Distribution in rat heart 4 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14296 | Distribution in rat heart 6 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18342 | Tested for the tissue distribution of Br activity at 30 min in lung following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14149 | Distribution in rat heart 15 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14509 | Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1853652 | Antibacterial activity against Mycobacterium avium ATCC 25921 assessed as inhibition of bacterial growth incubated upto 3 weeks hrs by resazurin dye based double-dilution method | 2021 | RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11 | Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from |
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID14487 | Distribution in rat skin 15 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14309 | Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14345 | Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14344 | Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14152 | Distribution in rat heart 30 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14329 | Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14326 | Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14315 | Distribution in rat liver 1 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1853649 | Antibacterial activity against Mycobacterium smegmatis mc2 155 assessed as inhibition of bacterial growth incubated upto 3 weeks hrs by resazurin dye based double-dilution method | 2021 | RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11 | Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from |
| AID14313 | Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14303 | Distribution in rat intestine 5 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18339 | Tested for the tissue distribution of Br activity at 30 min in brain following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14336 | Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14140 | Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14125 | Distribution in blood of rat 5 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14145 | Distribution in rat fat 4 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1853668 | Synergistic antibacterial activity against Mycobacterium smegmatis mc2 155 assessed as fold reduction in MIC value at 8 ug/ml in presence of clarithromycin by checkerboard assay | 2021 | RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11 | Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from |
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID14339 | Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18332 | Tested for the tissue distribution of Br activity at 120 min in lung following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14133 | Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14328 | Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14506 | Distribution in rat uterus 30 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| AID14491 | Distribution in rat skin 4 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14341 | Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18142 | Tested for the tissue distribution of Br activity at 120 min in blood following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14131 | Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14302 | Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14141 | Distribution in rat fat 15 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18347 | Tested for the tissue distribution of Br activity at 45 min in lung following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID14490 | Distribution in rat skin 30 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14317 | Distribution in rat liver 30 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18349 | Tested for the tissue distribution of Br activity at 60 min in brain following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14492 | Distribution in rat skin 5 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| AID14310 | Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14129 | Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14308 | Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14143 | Distribution in rat fat 2 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14306 | Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14138 | Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18344 | Tested for the tissue distribution of Br activity at 45 min in brain following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14342 | Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14338 | Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14146 | Distribution in rat fat 5 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14322 | Distribution in rat lungs 15 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14497 | Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14331 | Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID18352 | Tested for the tissue distribution of Br activity at 60 min in lung following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14332 | Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID18335 | Tested for the tissue distribution of Br activity at 15 min in kidney following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14325 | Distribution in rat lungs 30 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID311933 | Inhibition of ASM in rat PC12 cells assessed as residual activity at 10 uM | 2008 | Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2 | Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. |
| AID18336 | Tested for the tissue distribution of Br activity at 15 min in liver following intravenous injection in rat at the dose of 0.2 mg/kg | 1980 | Journal of medicinal chemistry, Jan, Volume: 23, Issue:1 | Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat. |
| AID14504 | Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14307 | Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID14134 | Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID14319 | Distribution in rat liver 5 min after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1853645 | Competitive inhibition of Mycobacterium tuberculosis Eis assessed as reduction in Eis-mediated kanamycin acetylation preincubated for 10 mins followed by substrate addition and measured for 2 to 5 mins using acetyl-CoA as substrate in presence of kanamyci | 2021 | RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11 | Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from |
| AID14127 | Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| AID14128 | Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1347116 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347112 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347115 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347111 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347113 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347109 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347122 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347126 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347121 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347127 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347128 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347114 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347123 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347129 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347125 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347118 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347117 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347124 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347110 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347119 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 28 (26.92) | 18.7374 |
| 1990's | 23 (22.12) | 18.2507 |
| 2000's | 28 (26.92) | 29.6817 |
| 2010's | 18 (17.31) | 24.3611 |
| 2020's | 7 (6.73) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (38.03) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 23 (21.10%) | 5.53% |
| Reviews | 5 (4.59%) | 6.00% |
| Case Studies | 13 (11.93%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 68 (62.39%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics for the Prevention of Relapse in Long-term Stabilized Schizophrenic Patients: a Randomized, Single-blind, Longitudinal Trial [NCT02307396] | Phase 4 | 21 participants (Actual) | Interventional | 2015-02-01 | Completed | ||
| Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567] | Phase 3 | 407 participants (Actual) | Interventional | 2015-01-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||